Preoperative, Intraoperative and Postoperative Corticosteroid Use as an Adjunctive Treatment for Rhegmatogenous Retinal Detachment
- Autori: Bonfiglio, V; Reibaldi, M; Macchi, I; Fallico, M; Pizzo, C; Patane, C; Russo, A; Longo, A; Pizzo, A; Cillino, G; Cillino, S; Vadalà, M; Rinaldi, M; Rejdak, R; Nowomiejska, K; Toro, MD; Avitabile, T; Ortisi, E
- Anno di pubblicazione: 2020
- Tipologia: Articolo in rivista
- Parole Chiave: rhegmatogenous retinal detachment; vitrectomy; dexamethasone; triamcinolone; fluocinolone; corticosteroids;
- OA Link: http://hdl.handle.net/10447/433919
The treatment for rhegmatogenous retinal detachment (RRD) is surgery, including pars plana vitrectomy (PPV) and scleral buckling (SB). Despite surgical advances, degeneration of the photoreceptors and post-operative complications, such as proliferative vitreoretinopathy (PVR), often occurs as the result of inflammation, preventing complete visual recovery or causing RRD recurrence. There is increasing evidence that in the presence of RRD, the activation of inflammatory processes occurs and the surgery itself induces an inflammatory response. This comprehensive review focuses on the use of different formulations of corticosteroids (CCS), as an adjunctive treatment to surgery, either PPV or SB, for RRD repair. The purpose was to review the efficacy and safety of CCS in improving functional and anatomical outcomes and in preventing postoperative complications. This review is organized according to the timing of CCS administration: preoperative, intraoperative, and postoperative. The evidence reviewed supported the role of the pre-operative use of CCS in the treatment of combined RRD and choroidal detachment (CD), reducing CD height. No solid consensus exists on intraoperative and postoperative use of CCS to treat and prevent postoperative complications. However, a large randomized clinical trial including more than 200 eyes suggested that oral prednisone after surgery decreases the rate of postoperative grade B PVR.